Adaptive clinical trials in tuberculosis: Applications, challenges and solutions

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 6, 2015, Pages 626-634

  Davies, G R ^a   Phillips, P P J ^b   Jaki, T ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Drug development; Sequential trials; Statistics; Tuberculosis

Indexed keywords

LINEZOLID; TUBERCULOSTATIC AGENT;

CLINICAL STUDY; DRUG EFFICACY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FACTORIAL DESIGN; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SAMPLE SIZE; STUDY DESIGN; TUBERCULOSIS; COMBINATION DRUG THERAPY; DRUG DEVELOPMENT; METHODOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84929410434     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0988     Document Type: Review

References (59)

1. Ginsberg A M, Spigelman M. Challenges in tuberculosis drug research and development. Nature Med 2007; 13: 290-294.
2. Davies G R. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinb) 2010; 90: 171-176.
3. Phillips P P J, Fielding K, Nunn A J. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLOS ONE 2013; 8: e63840.
4. Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010; 14: 663-664.
5. Merle C S, Fielding K, Sow O B, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371: 1588-1598.
6. Jindani A, Harrison T S, Nunn A J, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371: 1599-1608.
7. Gillespie S H, Crook A M, McHugh T D, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-1587.
8. Redmond C K, Colton T. Biostatistics in clinical trials. Chichester, UK: John Wiley & Sons, 2001.
9. Bauer P, Einfalt J. Application of adaptive designs: a review. Biom J 2006; 48: 493-506.
10. Vandemeulebroecke M. Group sequential and adaptive designs: a review of basic concepts and points of discussion. Biom J 2008; 50: 541-557.
11. Food and Drug Administration. Draft guidance for industry: adaptive design clinical trials for drugs and biologics. Washington DC, USA: FDA, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm201790.pdf Accessed March 2015.
12. Whitehead J. The design and analysis of sequential clinical trials. Chichester, UK: John Wiley & Sons, 1997.
13. Jennison C, Turnbull B W. Group sequential methods with applications to clinical trials. Boca Raton, FL, USA: Chapman & Hall/CRC, 2000.
14. Todd S. A 25-year review of sequential methodology in clinical studies. Stat Med 2007; 26: 237-252.
15. Stallard N, Todd S. Seamless Phase II/III designs. Stat Methods Med Res 2011 1; 20: 623-634
16. Sharma M R, Stadler W M, Ratain M J. Randomized Phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011; 103: 1093-1100.
17. Lee M, Lee J, Carroll M W, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
18. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
19. ClinicalTrials.gov. Evaluation of 8 weeks of treatment with the combination of moxifloxacin, PA-824 and pyrazinamide in patients with drug sensitive and multidrug-resistant pulmonary tuberculosis (TB). Bethesda, MD, USA: National Institutes of Health, 2015. http://clinicaltrials.gov/ct2/show/study/NCT0149841 Accessed March 2015.
20. Multiple testing problems in pharmaceutical statistics. Biostatistics series. Dmitrienko A, Tamhane A C, Bretz F, eds. Boca Raton, FL, USA: Chapman Hall/CRC, 2010.
21. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1.
22. Burman W J, Goldberg S, Johnson J L et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338.
23. Conde M B, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
24. Dorman S E, Johnson J L, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
25. Dawson R,Narunsky K, Hoffman J, et al. A randomised, 2-stage design trial of rifapentine 450 mg or 600 mg in place of rifampicin for intensive phase treatment of smear-positive pulmonary TB. 45th Union World Conference of Lung Health Barcelona, Spain, 28October-1November 2014. AbstractOAP- 345-31. Int J Tuberc Lung Dis 2014; 18 (Suppl 1): S407-S408.
26. Thall P F, Simon R, Ellenberg S S. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45: 537-547.
27. StallardN, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Stat Med 2003; 22: 689-703.
28. Friede T, Stallard N. A comparison of methods for adaptive treatment selection. Biom J 2008; 50: 767-781.
29. Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biom J 2008; 50: 515-527.
30. Rosenberger W F. Randomized play-the-winner clinical trials: review and recommendations. Control Clin Trials 1999; 20: 328-342.
31. Zhou Y, Whitehead J, Bonvini E, Stevens JW. Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. Pharm Stat 2006; 5: 125-133.
32. Whitehead J, Thygesen H, Whitehead A. Bayesian procedures for phase I/II clinical trials investigating the safetyand efficacy of drug combinations. Stat Med 2011; 30: 1952-1970. http://www.pih.org/blog/a-new-partnership-to-change-mdr-tbtreatment-around-the-world Accessed March 2015.
33. Partners in Health. A new partnership to change MDR-TB treatment around the world. Boston, MA, USA: PIH, 2009- 2015. http://www.pih.org/blog/a-new-partnership-to-changemdr-tb-treatment-around-the-world Accessed March 2015.
34. Bretz F, Schmidli H, Konig F, Racine A, Maurer W. Confirmatory seamless Phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J 2006; 4: 623-634.
35. Diacon A H, Pym A, Grobusch M P, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
36. Skripconoka V, Danilovits M, Pehme L, et al. Delaminid improves outcomes and reduces mortality in multi-drug resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
37. Schmidli H, Bretz F, Racine A, Maurer W. Confirmatory seamless Phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biom J 2006; 4: 635-643.
38. Wason J M, Stecher L, Mander A P. Correcting for multipletesting in multi-arm trials: is it necessary and is it done? Trials 2014; 15: 364.
39. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med 2005; 24: 3697-3714.
40. Royston P, Barthel F, Parmar M, Choodari-Oskooei B, Isham V. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials 2011; 12: 81.
41. Bookman M A; the Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin vs combinations with Gemcitabine (G), PEG-liposomal doxorubicin (D), ortopotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. 42nd Annual Meeting of the American Society ofClinical Oncology, 2-6 June 2006, Atlanta, GA, USA, Proc ASCO 2006. Abstract 5002.
42. ICON6 Trial Development Group. ICON6 Protocol. London, UK: MRC Clinical Trials Unit, 2007.
43. Sydes M R, Parmar M K, James N D, et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10: 39.
44. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. Biometrika 2012; 99: 494-501.
45. Wason J M S, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res 2013 Nov 28. [Epub ahead of print]
46. Parmar M K, Barthel F M, Sydes M et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008; 100: 1204-1214.
47. Choodari-Oskooei B, Parmar M K B, Royston P, Bowden J. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome. Trials 2013; 14: 23.
48. Pocock S J.When (not) to stop a clinical trial for benefit. JAMA 2005; 294: 2228-2230.
49. ClinicalTrials.gov. Evaluation of SQ109, high-dose rifampicin, and moxifloxacin in adults with smear-positive pulmonary TB in a MAMS design. Bethesda, MD, USA: National Institutes of Health, 2015. http://clinicaltrials.gov/show/NCT01785186 Accessed March 2015.
50. Freidlin B, Korn E, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res 2008; 14: 4368-4371.
51. Wason J, Stallard N, Bowden J, Jennison C. A multi-stage dropthe- losers design for multi-arm clinical trials. Stat Methods Med Res 2014 Sep 16. [Epub ahead of print]
52. Wallis R S, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLOS ONE 2013; 8: e71116.
53. Food & Drug Administration. Draft Guidance: Pulmonary tuberculosis: developing drugs for treatment. Washington DC, USA: FDA, 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM373580.pdf Accessed March 2015.
54. Bratton D J, Phillips P P, Parmar M K. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. BMC Med Res Methodol 2013; 13: 139.
55. Food&Drug Administration. Draft Guidance: co-development of two or more unmarketed investigational drugs for use in combination. Washington DC, USA: FDA, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf Accessed March 2015.
56. Green S, Liu P-Y, O'Sullivan J. Factorial design considerations. J Clin Oncol 2002; 20: 3424-3430.
57. Wolbers M, Heemskerk D, Chau T T, et al. Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis. Trials 2011; 12: 26.
58. Phillips P P, Gillespie S H, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis 2012; 205 (Suppl 2): S250-S257.
59. Fox W, Ellard G, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units 1946-1986, with subsequent relevant publications. Int J Tuberc Lung Dis 1999; 10 (Suppl 2): S231-S279.